Form 4: Cartesian Therapeutics Insider Stock Transaction

Elizabeth Hoge, a director at Cartesian Therapeutics, Inc., reported a conversion of Series A Preferred Stock into common stock and related beneficial ownership changes.

Summary

• Elizabeth Hoge, a director and 10% owner of Cartesian Therapeutics, Inc. (RNAC), reported transactions on April 2, 2026.
• The Seven One Eight Three Four Irrevocable Trust, for which Hoge is a trustee, converted a portion of its Series A Non-Voting Convertible Preferred Stock into common stock.
• This conversion resulted in the acquisition of 758,001 shares of common stock by the Trust.
• The Trust now beneficially owns 5,313,261 shares of common stock, held as trustee.
• Additional common stock holdings of 506,999 shares are held by the reporting person's spouse.
• The Series A Preferred Stock conversion involved 22,740.03 shares, resulting in 758,001 shares of common stock.
• These securities represent merger consideration from the acquisition of a private Delaware corporation in November 2023 and private placement purchases.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a standard insider transaction related to past corporate events rather than new strategic or financial developments.

Positives

• Conversion of preferred stock into common stock can indicate confidence in the company's future value.
• The reporting person, Elizabeth Hoge, maintains a significant beneficial ownership stake, indicating continued commitment.
• The transaction is linked to a merger and private placement, suggesting past strategic corporate actions.

Negatives

• The filing does not explicitly detail the financial implications or valuation of the converted securities.
• A portion of the Series A Preferred Stock held by the Trust is subject to a beneficial ownership limitation, the details of which are not provided.

Risks

• The beneficial ownership limitation on remaining Series A Preferred Stock could restrict future actions or holdings.
• The nature of the merger consideration and private placement securities may carry inherent risks not detailed in this filing.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the conversion of preferred stock into common stock by a significant insider may imply a positive outlook on the company's future prospects.

Management Comments

• The reporting person is a trustee of the Trust.
• These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The conversion of preferred stock into common stock is a common event for companies that have undergone mergers or private placements, reflecting the maturation of those transactions.

Stakeholder Impact

• Shareholders: The conversion increases the number of outstanding common shares, which could dilute existing ownership if not accompanied by a corresponding increase in market capitalization. However, it also reflects the fulfillment of merger consideration.
• Management/Insiders: Elizabeth Hoge, as a director and trustee, is directly involved in these transactions, reinforcing her stake and potential alignment with common shareholders.

Next Steps

• The Trust's remaining Series A Non-Voting Convertible Preferred Stock is subject to a beneficial ownership limitation.

Key Dates

Keywords

Form 4, Insider Transaction, Beneficial Ownership, Cartesian Therapeutics, Elizabeth Hoge, Series A Convertible Preferred Stock, Common Stock, Merger Consideration, SEC Filing, RNAC